Taking into account that accumulation of hyperphosphorylated tau is a hallmark of AD and other neurodegenerative disorders, inhibitors of kinases, particularly of glycogen sintase kinase 3β and of Fyn, a member the Src-family of non-receptor tyrosine kinases, have drawn much attention for their anti-tauopathy potential [80]. The gene discussed is MAPT; the disease is tauopathy.